Cannabis Stock News- Investing in Cannabis and Hemp Stocks

Friday, April 7, 2017

Canadian Cannabis Stock News: Valens GroWorks (CSE: $VGW) Acquires Licensed Cannabis Testing Lab

VANCOUVER, BRITISH COLUMBIA - April 7, 2017 (Investorideas.com Newswire) Valens GroWorks Corp. (CSE:VGW)(CSE:VGW.CN) (the "Company" or "Valens") is pleased to announce completion of the acquisition of Supra THC Services Inc. ("SUPRA"), a Health Canada-licensed cannabis testing lab with an established Kelowna-based scientific team supporting its operations.

Valens acquired all of the issued and outstanding shares of SUPRA for $3.75 million, satisfied through the issuance of three million shares of Valens. The total share consideration is subject to a regulatory four month hold period as well as a 36-month escrow agreement.

SUPRA holds a Health Canada Dealer's License which allows for the possession of cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis.

SUPRA's mission is to become a leading Analytical Service Provider to the cannabis industry. Revenue-generating activities are expected to include analytical services, consulting services, and contract Research and Development. The company will also produce oils and ointments using a proprietary solvent-free extraction approach that produces an organic 100% cannabis oil product.

SUPRA is led by Dr. Rob O'Brien, who also recently joined Valens Agritech Ltd. ("VAL"), the Company's wholly-owned subsidiary, as its President and Chief Science Officer (CSO). Dr. O'Brien is an expert in analytical instrumentation, has established a number of advanced analytical laboratories, and founded Supra Research and Development, the first spin-off company from the University of British Columbia's Okanagan campus, created to commercialize innovative biomass extraction technology.

Dr. O'Brien stated, "Having both Valens Agritech and Supra THC Services as wholly-owned subsidiaries of Valens GroWorks provides us with a gateway to the capital markets and the necessary currency to execute on our strategic vision. Our immediate objective is to secure the infrastructure necessary to become a leading-edge cannabis-based enterprise in one of the fastest growing sectors of the global economy."

About Valens GroWorks Corp.

Valens GroWorks Corp is a CSE-listed company with an aggressive acquisition strategy in progress, providing management, consulting, testing and support services to domestic and international licensees, as well as financing the buildout of established, licensed operations in Arizona. The Company seeks to capture a broad spectrum of medical marijuana users, as well as recreational users once legalized, in pursuit of its ambitious Plants to Premium Products "P2P" objectives.

The Company's wholly-owned subsidiary, Valens Agritech Ltd., is a post-inspection applicant anticipating receipt of a Controlled Drugs and Substances Dealer's Licence for the cultivation and processing of marijuana. Based in the Okanagan Valley of British Columbia, VAL anticipates participation in selective clinical trial programs researching the efficacy of medical cannabis.

The Company is engaged under a letter of intent to acquire 100% of Royal Green Acres Manufacturing Ltd., a final review-stage applicant for a License to Produce ("LP") under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR). The proposed buildout to be funded is a 50,000-sf, indoor, state-of-the-art, medicinal cannabis production and processing facility located on 5 acres just outside Nanaimo, British Columbia.

On behalf of the Board of Directors,

VALENS GROWORKS CORP.

Robert van Santen, Chief Executive Officer

Notice regarding Forward Looking Statements

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.Contact Information

Valens GroWorks Corp.
Greg Patchell
+1.250.860.8634

Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory

Join our Group on Linkedin - Marijuana / Hemp Stocks - News and Trends in Green Investing

Global Cannabis Investing - features Investor Ideas Cannabis news

Get News Alerts on Marijuana Stocks

Watch the 420 Cannabis Investor video

https://www.youtube.com/watch?v=e2zFezO580Y&t=54s

More Info:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Canabo Medical Inc. (TSX VENTURE: $CMM) (OTCQB: $AMDF) observational study finds nearly fifty per cent drop in benzodiazepine use within months of #cannabis treatment

Milestone study shows dramatic reduction in pharmaceutical reliance among Canadian medical cannabis patients

TORONTO, ON - April 7, 2017 (Investorideas.com Newswire) Today, Canabo Medical Inc. (TSX VENTURE: CMM) (OTCQB: CAMDF) ("Canabo" or the "Company") released the results of a new, landmark observational study that connects doctor-supervised medical cannabis treatments to a sharp drop in benzodiazepine reliance among Canadian patients.

Research conducted over the past year revealed that 40 per cent of patients who were prescribed medical cannabis to treat pain and anxiety eliminated the use of benzodiazepines within 90 days. That percentage increased to 45 per cent within a year of cannabis treatment. The findings were announced by Dr. Neil Smith during a presentation at the Canadian Consortium for the Investigation of Cannabinoids (CCIC) event in Toronto.

Canabo, which operates 15 cannabinoid clinics across Canada under the brand CMClinics, partnered with a consortium of medical research experts to analyze data from more than 1,500 patients with the aim of understanding how cannabis interacts with or lessens the need for pharmaceutical treatments. Preliminary findings in late 2016 indicated a downward trend in benzodiazepine use -- a trend that was confirmed after additional investigation and included in the Reduction of Benzodiazepine Use in Patients Prescribed Medical Marijuana report. The team responsible for the peer-reviewed report has shared their findings with several Canadian medical journals and details are expected to soon appear in the Dalhousie Medical Journal.

In Canada, 10 per cent of the general population use benzodiazepines daily, with common side-effects such as sedation, dizziness, drowsiness, unsteadiness, headache and memory impairment. Long-term benzodiazepine use is also associated with complications including problems with concentration, tolerance, addiction and overdose.

"We wanted to take a close look at the likelihood of continued benzodiazepine usage after commencing medical cannabis treatments and to be perfectly honest, the results are extremely promising," said Dr. Neil Smith, Executive Chairman of Canabo. "When conducting this type of research, experts are typically encouraged by an efficacy rate in the neighbourhood of 10 per cent. To see 45 per cent effectiveness demonstrates that the medical cannabis industry is at a real watershed moment."

Augmenting pharmaceutical regimes with cannabinoid treatments

The study isolated a group of 146 patients from a database of individuals being treated for a wide variety of pain and other disorders for approximately one-year. Each patient was referred by a primary physician or specialist and thoroughly assessed by CMClinic's own doctors before being prescribed cannabis as supplemental treatment. Additional patient details include:

The average age of the sample of patients using benzodiazepines on initial contact with the company is 48 years-old
Nearly 43 per cent (42.9%) of that group report a work status of either temporarily or permanently disabled
Nearly 60 per cent (59.9%) of the patients are female
Those individuals taking benzodiazepines have primary conditions that are representative of all CMClinic patients
Well more than half (61.3%) are primarily interested in treatment for a pain condition, 27.4 per cent for a psychiatric condition and 11.3 per cent for a neurological condition

In all cases, patients remained under the care of the referring doctor and all were examined in detail to understand the effect of cannabinoid treatments on benzodiazepine use.

Canabo is also collecting data as to what extent cannabis serves as a substitute or effective complement to traditional opioid therapies and today's report is expected to be the first in a series that examines the role of cannabis in modern therapies.

"To say that we're encouraged is an understatement but there's a lot of work still to be done," added Dr. Smith. "We hope to conduct formal trials both in-house and in collaboration with others pending further analysis of what we believe to be one of the most promising advancements in many years."

About Canabo Medical Inc.

Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada's largest physician led referral-only clinics for medical cannabis. Established in 2014, Canabo has 15 clinics across Canada with several additional locations set to open in 2017.

Canabo operates referral-only medical clinics dedicated to evaluating the suitability of prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress.

Forward-Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect Canabo Medical Inc.'s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Canabo's actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of opening clinics, regulatory changes, competition, approvals and other business and industry risks.

The forward-looking statements in this press release are also based on several assumptions which may prove to be incorrect. Forward-looking statements contained in this press release represent views only as of the date of this release and are presented for the purpose of assisting potential investors in understanding Canabo's business, and may not be appropriate for other purposes. Canabo does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to consult with a professional investment advisor.

For further information, please contact:

Ms. Madeline Whittaker
Telephone: +1 (902) 334-1700
www.canabocorp.com

Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory

Join our Group on Linkedin - Marijuana / Hemp Stocks - News and Trends in Green Investing

Global Cannabis Investing - features Investor Ideas Cannabis news

Get News Alerts on Marijuana Stocks

Watch the 420 Cannabis Investor video

https://www.youtube.com/watch?v=e2zFezO580Y&t=54s

More Info:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

West Virginia Legislature Approves Medical Marijuana Bill

Gov. Jim Justice is expected to sign SB 386 into law, making West Virginia the 29th state to adopt an effective medical marijuana law

CHARLESTON, W. Va. - April 7, 2017 (Investorideas.com Newswire) A medical marijuana bill received final approval in the West Virginia Legislature on Thursday and is headed to the desk of Gov. Jim Justice. He has publicly expressed support for legal access to medical marijuana and is expected to sign the bill into law, making West Virginia the 29th state to adopt an effective medical marijuana law.

SB 386, introduced by Sen. Richard Ojeda (D-Logan), received initial approval from the Senate last week (28-6). The House substantially amended the bill before approving it on Tuesday (76-24). The Senate passed the new version on concurrence Wednesday afternoon (28-6), along with some minor amendments, and the House signed off on the final version Thursday (74-24).

"Some of the House amendments to the bill are concerning, but it still has the potential to provide relief to thousands of seriously ill West Virginians," said Matt Simon of the Marijuana Policy Project (MPP), who is a West Virginia native and graduate of West Virginia University. "We commend the Legislature for passing this compassionate and much-needed legislation, and we encourage Gov. Justice to sign it into law.

"This will be an important and, in some cases, life-saving program," Simon said. "It is critical that the state implement it promptly. We are committed to working with officials to make sure the program is as effective as possible and to get it up and running in a timely fashion. Many patients cannot afford to wait much longer."

SB 386, titled the West Virginia Medical Cannabis Act, charges the Bureau of Public Health with regulating medical marijuana growers, processors, and dispensaries. Patients with specifically listed qualifying medical conditions will be allowed to use extracts, tinctures, and other preparations of marijuana, but not marijuana in flower or leaf form. This differs from the original version of the bill and the medical marijuana programs in most other states. A summary of SB 386 is available at http://bit.ly/2nbUAq3.

"There is nearly universal support for legalizing medical marijuana in the U.S., and it spans the political spectrum," Simon said. "This is the third state in a row to pass a medical marijuana bill through a Republican-controlled House and Senate. Hopefully, this is a trend that will continue with some other states and at the federal level."

A February 2017 Quinnipiac University Poll found 93% of U.S. voters think marijuana should be legal for medical purposes. Twenty-eight states, the District of Columbia, and the U.S. territories of Guam and Puerto Rico have enacted effective medical marijuana laws, and 18 states have adopted medical marijuana laws that are ineffective because they are either unworkable or exceptionally restrictive. Once S.B. 386 is signed into law, only three states in the nation — Idaho, Indiana, and Kansas — will lack any form of medical marijuana law.

The Marijuana Policy Project is the nation’s largest marijuana policy organization. For more information, visit http://www.MarijuanaPolicy.org.

Contact

Matt Simon
603-391-7450, msimon@mpp.org

Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory

Join our Group on Linkedin - Marijuana / Hemp Stocks - News and Trends in Green Investing

Global Cannabis Investing - features Investor Ideas Cannabis news

Get News Alerts on Marijuana Stocks

Watch the 420 Cannabis Investor video

https://www.youtube.com/watch?v=e2zFezO580Y&t=54s

More Info:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

This Week’s Cannabis and Hemp Stocks Added; (TSX.V: $HEMP), (TSX.V: $THCX), ($SNNC) and ETF (TSX: $HMMJ)

This Week’s Cannabis and Hemp Stocks Added; (TSX.V: $HEMP), (TSX.V: $THCX), ($SNNC) and ETF (TSX: $HMMJ)

Other New Marijuana/Hemp Stocks: $MMG.AX, $SGMD, $ZRZH

Point Roberts, WA, Delta BC – April 7, 2017 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its cannabis /hemp stock directory for investors following the sector.

The biggest news for this week is the listing of Horizons Medical Marijuana Life Sciences ETF (TSX: HMMJ.TO), the first North American Marijuana ETF which is now trading on the TSX.

Additionally, new stocks include a hemp company that sells bulk hemp seeds and oils along with hemp infused food products, medical marijuana companies, a company providing insurance solutions and employment services for the marijuana sector and a commercial greenhouse company that is also involved in crop care automation.

Read this release in full at http://www.investorideas.com/news/2017/marijuana/04071Stocks.asp

Investorideas.com cannabis/marijuana and hemp content now includes: http://cannabisstocknews.blogspot.com on Blogger.com: the Investorideas.com news and stock directory pages, a cannabis investor group on Linkedin.com , the 420 Cannabis Investor ideas www.420cannabisinvestorideas.com, and the AI site Global Cannabis Investing at www.Globalcannabisinvesting.com

New Marijuana Companies Added to the Investor cannabis stock directory:

Hempco Food and Fiber Inc (TSX:HEMP.V; HMPPF) manufactures and distributes hemp food products for human and animal consumption in the United States, Canada, Mexico/Latin America, Asia/Pacific, and Europe. It produces bulk hulled hemp seeds, hemp protein powders, and hemp seed oil under the PlanetHemp brand name. The company is headquartered in Burnaby, Canada.

Horizons Medical Marijuana Life Sciences ETF (TSX:HMMJ.TO) seeks to replicate, to the extent possible, the performance of the North American Medical Marijuana Index, net of expenses. The North American Medical Marijuana Index is designed to provide exposure to the performance of a basket of North American publicly listed life sciences companies with significant business activities in the marijuana industry.

Hydropothecary Corporation, The (TSX:THCX.V) is an authorized licensed producer and distributor of medical marijuana licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (Canada). Hydropothecary provides naturally grown and rigorously tested medical marijuana of uncompromising quality. Hydropothecary's branding, marijuana product offering, patient service standards and product pricing are consistent with THC's positioning as a premium brand for a legal source for medical marijuana within this new marketplace. In addition to medical marijuana production and sales, Hydropothecary explores various research and development opportunities for cannabinoid extracts, drugs and combinatory chemistry. In addition, the company is investigating the development and patenting of novel technologies related to medical marijuana, as well as the import and export of medical marijuana.

MMJ Phytotech Medical (ASX:MMJ.AX) is focused on becoming a large-scale cannabis producer, targeting direct supply to the growing Canadian medical and recreational markets which will have an estimated combined value of C$8-9 billion by 2024. The Company controls operations across the entire medicinal cannabis value chain through three business units, strategically located in favourable jurisdictions with supportive regulatory frameworks in place.

Sibannac Inc (OTC:SNNC) Sibannac HR (Powered by National PEO) is a cannabis industry friendly professional employment services organization providing the following: LABOR LAW COMPLIANCE, PAYROLL PROCESSING, HUMAN RESOURCES, EMPLOYEE HANDBOOKS, TRAINING & DEVELOPMENT, LABOR LAW COMPLIANCE, UNEMPLOYMENT CLAIMS ADMINISTRATION, HEALTH INSURANCE & ANCILLARY BENEFITS, CANNABIS FRIENDLY 401K PLAN, WORKERS’ COMPENSATION ADMINISTRATION, SAFETY & RISK MANAGEMENT, SAFETY PLANS, OSHA COMPLIANCE, RECRUITING & EMPLOYEE RETENTION Additionally, we provide insurance solutions for the cannabis industry through our partner company, Nexus Partners Insurance Solutions.

Sugarmade Inc (OTC:SGMD) is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade's brands include CarryOutSupplies.com, Sugarmade Tree Free Paper, FreeHand ThumbTray and CannaShroud™. During early 2017, the company will be launching Sriracha Stix, a revolutionary culinary seasoning product under official license from Irwindale, California-based Huy Fong Foods, Inc., the maker of Sriracha Hot Chili Sauce.

Zerez Holdings (OTC:ZRZH) is a public equity corporation focused on the advanced agriculture and cannabis industries with plans to grow through acquisition, strategic alliances, and proprietary intellectual property. The company’s wholly owned subsidiary Next Generation Farming Inc. provides turnkey commercial greenhouses and automation systems that improve yields and decrease water consumption for cultivators of organic food and cannabis crops.

The complete marijuana/hemp stock list available for purchase in a PDF format:

http://www.investorideas.com/dirs/stocklist.asp

Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector. Listing for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format. The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas

Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.

Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.

The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Services for Publicly traded and private companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution,social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Contact Investorideas.com

800-665-0411

Marijuana / Hemp Stocks

Like Marijuana / Hemp Stocks? View our Marijuana / Hemp Stocks Directory

Join our Group on Linkedin - Marijuana / Hemp Stocks - News and Trends in Green Investing

Global Cannabis Investing - features Investor Ideas Cannabis news

Get News Alerts on Marijuana Stocks

Thursday, April 6, 2017

Cannabis Stock News: Abattis Bioceuticals (OTCQB: $ATTBF) (CSE: $ATT) Gets Added to the Marijuana Index by MJIC

Vancouver, British Columbia - April 6, 2017 (Newsfile Corp.) (Investorideas.com Newswire) Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis"), is pleased to announce it has officially been added to The Marijuana Index, within the Biotechnology sector.

The North American Marijuana Index tracks the leading public cannabis companies operating in the United States and Canada and gives investors up to date, centralized news on the securities deemed to be well positioned within the multi-billion dollar cannabis industry. Selected companies must meet stringent trading guidelines including having a minimum market capitalization of $30 million and daily trading volumes of above $400K.

"We are delighted to have Abattis added to the The Marijuana Index and look forward to sharing our story with investors closely tracking this exciting sector," stated Abattis CFO, Rene David. "As we approach sector legalization, we'll start to see markets broaden their reach from the closely covered cultivation and growing players to those advancing the technology and biosciences side of the cannabis industry," added Mr. David.

Abattis' subsidiary Northern Vine Labs is set to open its doors this month and will legally be able to test dried plant products, extracts, derivatives and edibles for licensed producers and patients under the ACMPR regulatory framework. Management will continue to provide timely updates on these developments in the coming weeks.

About Abattis Bioceuticals Corp.

Abattis is a specialty agricultural technology and biotechnology company which aggregates, integrates, and invests in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

About Northern Vine Canada Inc.

Northern Vine Labs™ is licensed by Health Canada (Dealers License) for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the legal Canadian Cannabis market.

"Rene David"
Rene David, CFO, Director

For further information, contact the Company at (604) 336-0881 or at news@abattis.com.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time. NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory

Join our Group on Linkedin - Marijuana / Hemp Stocks - News and Trends in Green Investing

Global Cannabis Investing - features Investor Ideas Cannabis news

Get News Alerts on Marijuana Stocks

Watch the 420 Cannabis Investor video

https://www.youtube.com/watch?v=e2zFezO580Y&t=54s

More Info:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

about Investorideas.com

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .